One of Central America's most important recent developments is unfolding in a less visible but more tangible area for citizens: access to medicines.

March 17 (UPI) -- When Central American leaders talk about integration, the conversation often centers on trade, customs facilitation, or security cooperation. Yet one of the region's most important recent developments is unfolding in a less visible but far more tangible area for citizens: access to medicines. In early March, health regulators from Central America and the Dominican Republic gathered in Antigua Guatemala, where they agreed on a roadmap to move toward joint regulatory decisions on medicines, including biologics and biosimilars, within the regional health coordination framework linked to the Central American Integration System (SICA).

At first glance, this may sound like a technical issue reserved for specialists. In reality, it goes to the heart of whether regional cooperation can help people gain access to life-saving treatments more quickly and at lower cost. It also offers a rare opportunity for Central American integration to prove its value in ways that ordinary citizens can actually feel.

Why this matters to citizens

For years, countries in the subregion have evaluated similar medicines through separate national procedures, even when the scientific questions are largely the same. That duplication slows approvals and discourages pharmaceutical companies from introducing new treatments in smaller markets. The logic behind joint evaluation is straightforward. Countries can share parts of the scientific review, avoid duplicating work across multiple jurisdictions, and still maintain national authority over final approvals.

The Pan American Health Organization has supported this approach for several years and has noted that the regional joint evaluation mechanism was designed to ensure safety and effectiveness while potentially reducing registration timelines for covered medicines to less than three months.

Why biologics and biosimilars matter

The importance of the latest step lies in its focus on biologics and biosimilars, which are among the most complex and costly medicines in modern healthcare. These therapies are increasingly essential in the treatment of conditions such as cancer, diabetes, and autoimmune disorders. Biologics are derived from living organisms such as cells and bacteria. Biosimilars are what their name suggests, medicines that are similar to biologics in all essential respects, but cheaper to produce. When properly evaluated and regulated, they can expand access by increasing competition and lowering costs.

For Central America, the challenge of access to medicines is not only about price. It is also about time. Delays in sanitary registrations can slow the arrival of new therapies and limit the options available to doctors, hospitals, and patients. International assessments have highlighted persistent delays in some countries, driven by paper-heavy procedures and regulatory backlogs that continue to affect both new registrations and renewals.

For patients, these delays are not simply administrative inconveniences. They can mean waiting longer for treatment or finding fewer affordable options when care is needed. For public health systems operating under tight budgets, this can make an already difficult situation worse. This is precisely why initiatives such as regional regulatory cooperation matter. They represent the kind of practical integration that can improve everyday life.

From technical coordination to public benefit

Having previously served as Chief of Staff to the Secretary General of the Central American Integration System, I witnessed firsthand how regional cooperation can generate tangible public benefits when it moves beyond declarations and begins to shape shared public policy. One important precedent has been the region's experience with joint negotiation and procurement of medicines. Through coordinated purchasing mechanisms, Central American countries have secured better prices and improved availability for their public health systems.

These efforts reflect something deeper than administrative coordination. For decades, the aspiration behind Central American integration has been what many describe as the Central American Dream: the idea that regional cooperation should ultimately improve the lives of ordinary people. Integration was never meant to exist only in treaties or institutions. Its purpose has always been to expand opportunity and strengthen well-being in ways that no country could achieve on its own.

A stronger and more coordinated regulatory pathway for medicines could help bring that vision closer to reality. If companies can navigate a more predictable regional process, Central America may begin to look less like a fragmented group of small markets and more like a coherent entry point for innovation and investment.

A test for regional institutions

Yet this opportunity also exposes a broader institutional challenge. While the region seeks to deepen cooperation in areas as critical as public health, Central American governments have yet to reach an agreement on appointing a new SICA secretary-general. Leaving the organization's top leadership position vacant for an extended period risks weakening the very institutional framework that advances regional public policy.

Integration requires more than technical initiatives. It also requires political will and institutional stability. If governments expect regional cooperation to deliver concrete benefits-from faster regulatory approvals to more efficient procurement-they must also ensure that the institutions designed to coordinate those efforts are functioning effectively.

Central America has created many regional mechanisms over the decades. Some have delivered real progress. Others have produced more declarations than results. Access to medicines offers a different kind of test, one that citizens will immediately understand. When treatments arrive sooner, patients notice. When more affordable medicines reach the market, families and public health budgets notice as well.

Accelerating access to safe, effective medicines through regional regulatory cooperation could show that Central American collaboration genuinely improves lives-something rarely proven. For a region that has often promised more integration than it has delivered, improving access to medicines would be more than a technical success. It would be a reminder that the Central American Dream was always meant to become something real in the daily lives of its people.

Olinda Salguero is a Guatemalan leader in regional integration and peacebuilding in Latin America. She served for five years as Chief of Staff to the Secretary-General of the Central American Integration System (SICA) and is the President of the Esquipulas Foundation for Peace, Democracy, Development and Integration. She collaborates with initiatives of both the Global Peace Foundation and the Latin American & Caribbean Presidential Mission. Forbes has recognized her three times as one of the most powerful women in Central America. The views and opinions expressed here are solely those of the author.